Analyst Price Target is $0.25
▲ +2,456.24% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Viracta Therapeutics in the last 3 months. The average price target is $0.25, with a high forecast of $0.25 and a low forecast of $0.25. The average price target represents a 2,456.24% upside from the last price of $0.01.
Current Consensus is
Hold
The current consensus among 1 polled investment analysts is to hold stock in Viracta Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Read More
